Human-porcine MHC-I homology allows for antibody cross-reactivity

Nicole Forneris, Heather Levy, Christopher Burlak

Research output: Contribution to journalArticlepeer-review

Abstract

Pigs are especially useful large animal models, however, limited availability of commercially available antibodies for immunoblotting presents a significant obstacle facing preclinical xenotransplantation research. Major histocompatibility complex class I (MHC-I) molecule expression enhancement by nucleotide-binding oligomerization domain (NOD)-like receptor family with a caspase recruitment domain (CARD) containing caspase 5 (NLRC5) is fundamental to understanding porcine xenoantigen presentation. Swine Leukocyte Antigens (SLAs) are the porcine MHC homologs for human leukocyte antigens. SLA-I is a known xenoantigen that causes T cell activation. NLRC5, SLA-I, and B2M are all targets of immune modulation in genetically engineered pigs in xenotransplantation research with the goal to reduce SLA-I expression. In the present study, the human anti-NLRC5 (ab105411), anti-NLRC5 (ab117624), anti-NLRC5 N-terminal (ab178767), anti-HLA E (ab203082), anti-HLA E (ab135826), anti-HLA E (ab2216) and anti-β2M (ab75853) antibodies were examined using immunoblots for porcine cross-reactivity. The anti-human antibodies ab117624, ab105411, ab178767, ab2216, and ab75853 cross reacted with cognate proteins in porcine cell lysates. Antibody reagents from this study will allow for validation of NLRC5, B2M, MHC-I expression in future research studies. In addition, following the methodology described in this study for other xenotransplantation targets may provide an alternative to custom antibody development.

Original languageEnglish (US)
Pages (from-to)197-201
Number of pages5
JournalHLA
Volume96
Issue number2
DOIs
StatePublished - Aug 1 2020

Keywords

  • HLA-E
  • MHC class I
  • MHC-I
  • NLRC5
  • SLA-1
  • βM

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Human-porcine MHC-I homology allows for antibody cross-reactivity'. Together they form a unique fingerprint.

Cite this